摘要
背景:新发现的数据表明,非编码RNA(microrna 193a或mir-193 a)在不同类型的癌症中起着关键作用。 目的:根据文献资料,探讨miR-193a在不同肿瘤中的功能意义。 方法:对PubMed肿瘤中miR-193a的相关文献进行分析。 结果:一些研究证实miR-193a表达模式与癌症的分期、分级、对化疗的反应以及患者生存率有一定的相关性。此外,miR-193a可用于区分某些类型的癌症。在癌症中,miR-193a可以作为肿瘤抑制基因或致癌基因。到目前为止,预测了几种遗传因子(MAX、RXRα、XB130、p63、p73、AEG-1、HIFs、EGFR、DROSA、DGCR8、Dicer)和表观遗传因子(DNA甲基化和长非编码RNA)来控制miR-193A表达。它们对不同类型癌症的生物学行为有根本性的影响。 结论:MIR-193 a在肿瘤中具有重要作用,通过对其生物学行为控制因素的深入了解,有望成为肿瘤治疗的靶点。
关键词: mir-193a,癌症,化疗,预后,机制,甲基化。
图形摘要
Current Cancer Drug Targets
Title:Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Volume: 18 Issue: 7
关键词: mir-193a,癌症,化疗,预后,机制,甲基化。
摘要: Background: There is emerging data suggesting that the non-coding RNA (microRNA 193a or miR-193a) plays key roles in different types of cancers.
Objective: This review aims to investigate the functional significance of miR-193a in different cancers according to the information of literature.
Method: All the literature concerning miR-193a in cancer in PubMed are analysed.
Results: Several studies proved the association of miR-193a expression patterns with cancer’s stages, grades, response to the chemotherapy and even patient survival. Also, miR-193a can be used to differentiate some types of cancer. In cancer, miR-193a can act as a tumour suppressor gene or as an oncogene. Till now, several genetic factors (MAX, RXR α, XB130, P63, P73, AEG-1, HIFs, EGFR, Drosha, DGCR8, Dicer) and epigenetic factors (DNA methylation and long non-coding RNAs) were predicted to control miR-193a expression. They have fundamental effects on its biological behaviour in different types of cancers.
Conclusion: miR-193a has significant roles in cancer and can be targeted in the future for cancer therapy by better understanding of the factors that control its biological behaviour.
Export Options
About this article
Cite this article as:
Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression, Current Cancer Drug Targets 2018; 18 (7) . https://dx.doi.org/10.2174/1568009618666180308105727
DOI https://dx.doi.org/10.2174/1568009618666180308105727 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Molecular Phenotyping of Mouse Mutant Resources by RNA Expression Profiling
Current Genomics In Vivo Treatment Efficacy of Essential Oil Isolated from Seeds of <i>Momordica charantia</i> in Streptozotocin-Induced Diabetes Mellitus
Recent Patents on Biotechnology Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry The HIV-1 Tat Protein: A Multifaceted Target for Novel Therapeutic Opportunities
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacogenomics of Thiopurine S-methyltransferase
Current Clinical Pharmacology Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Cellular Targets for Anticancer Strategies
Current Drug Targets Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Treatment of Relapsed Acute Myeloid Leukaemia
Reviews on Recent Clinical Trials Advances in the Management of Malignant Hemopathies: The Role of Statins
Recent Patents on DNA & Gene Sequences Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation